LIFE SCIENCE - READY TO ROCKET LIST FOR 2020
2020
DIRECTORY
Life science - ready to ROCKET LIST FOR 2020 Life Science Technology includes Biotechnology, Pharmaceuticals, Medical Devices, and other innovations applying biology for improving our lives.
PAGE 1
LIFE SCIENCE - READY TO ROCKET LIST FOR 2020
PAGE 2
Table of Contents Aspect Biosystems Ltd.
4
Augurex Life Sciences Corp.
5
Eupraxia Pharmaceuticals Inc.
6
Fusion Genomics Corporation
7
Life360 Innovations Inc.
8
Microbiome Insights, Inc.
9
Navigate Surgical Technologies Inc.
10
Sitka Biopharma Inc.
11
Sonic Incytes Medical Corp.
12
Zucara Therapeutics
13
LIFE SCIENCE - READY TO ROCKET LIST FOR 2020
Aspect Biosystems Ltd.
ADDRESS
WEBSITE
1781 West 75th Avenue Vancouver, BC V6P 6P2 604-263-0502
www.aspectbiosystems.com TWITTER @aspectbiosys
PRIMARY CONTACT Tamer Mohamed, President & CEO
SECONDARY CONTACTs Natalie Korenic, Marketing & Communications Manager
ABOUT Aspect Biosystems is a privately held biotechnology platform company pioneering the microfluidic 3D bioprinting of human tissues. The Company’s proprietary technology has the potential to shape every aspect of human health by enabling the creation of human tissues for medical research, therapeutic discovery, and regenerative medicine. Aspect is focused on partnering with academic institutions and biopharma companies to facilitate high-value discovery and development. The Company is also advancing internal tissue therapeutic programs for regenerative medicine, with an initial focus on metabolic diseases and musculoskeletal injuries and disorders.
PAGE 4
LIFE SCIENCE - READY TO ROCKET LIST FOR 2020
Augurex Life Sciences Corp.
ADDRESS
WEBSITE
Unit 220 - 887 Great Northern Way Vancouver, BC V5T 4T5 604-637-3280
augurex.com TWITTER @Augurex
PRIMARY CONTACT Norma K. Biln, CEO
SECONDARY CONTACTs Simran Chahal, Senior Director, Strategic Partnershipss
ABOUT Augurex is an emerging commercial-stage, privately held biotechnology company located in Vancouver and is focused on the development and commercialization of biomarkers that transform patient clinical management for better disease outcomes. The company brings innovative blood tests and digital health, near-patient solutions to market to better inform clinical assessments for more precise care. The Augurex team is highly skilled in biomarker development, clinical validation and commercialization of healthcare products and services. Along with its integral team of Canadian contract researchers and manufacturers as well as world-renowned clinical rheumatology opinion leaders, Augurex is transforming autoimmune disease patient management, from early diagnosis to monitoring, with its 14-3-3Ρ (eta) biomarker portfolio of tests. By biologically informing a clinical assessment, Augurex’s biomarkers optimize patient management by personalizing clinical decision-making.
PAGE 5
LIFE SCIENCE - READY TO ROCKET LIST FOR 2020
Eupraxia Pharmaceuticals Inc.
ADDRESS
WEBSITE
201- 2590 Cadboro Bay Rd. Victoria, BC V8R 5G4 250-590-3968 info@eupraxiapharmaceuticals.com
eupraxiapharma.com TWITTER @eupraxia_pharma
ABOUT Eupraxia Pharmaceuticals has developed a novel platform that enables us to modulate drug release with precision. This ability allows us to tailor the profiles of proven drugs to improve safety, duration and efficacy. Starting with osteoarthritis (a degenerative joint disease), we are advancing a portfolio of drug candidates tailored to specific treatment needs in the areas of osteoarthritis, chronic pain, post-surgical pain and anti-infectives.
PAGE 6
LIFE SCIENCE - READY TO ROCKET LIST FOR 2020
Fusion Genomics Corporation
ADDRESS
WEBSITE
Room 1450, Discovery-1, 8999 Nelson Way Burnaby, BC V5A 1S6 604-428-7701
www.fusiongenomics.com TWITTER @fusiongenomics
PRIMARY CONTACT Mohammed Qadir, President & CEO
ABOUT Fusion Genomics is a molecular diagnostics company focused on transforming infectious disease through advanced genomic technologies. Fusion is applying novel DNA/RNA capture and informatics technologies to overcome the limitations of current infectiousdisease diagnostic tests, with the aim of preventing unnecessary deaths from infectious disease and halting the growing problem of drug resistance. The company’s rapid, highly sensitive, and cost-effective next-generation sequencing (NGS)-based tests have the potential to disrupt the $8 billion global infectious disease diagnostics market, replacing many conventional and molecular clinical lab tests.
PAGE 7
LIFE SCIENCE - READY TO ROCKET LIST FOR 2020
Contino (Life360 Innovations Inc.)
ADDRESS
WEBSITE
Suite 1200, 555 West Hastings Street Vancouver, BC 604-653-0360
mycontino.com
PRIMARY CONTACT
TWITTER @mycontino
Robert Orr, President & CEO
ABOUT Life360 Innovations is a Vancouver, BC based company that imagines, manufactures and distributes medical devices and products. Contino®, an easy-to-use, self-administered medical device that helps men control their stress urinary incontinence, is their flagship product. Contino® is licensed for sale in Canada by Health Canada and is now offered through partner clinics in BC and Ontario.
PAGE 8
LIFE SCIENCE - READY TO ROCKET LIST FOR 2020
Microbiome Insights, Inc.
ADDRESS
WEBSITE
2950 Tolmie St. Vancouver, BC V6R 4K6 604-356-4228
microbiomeinsights.com TWITTER @MB_Insights
PRIMARY CONTACT Malcolm Kendall, CEO
SECONDARY CONTACTs Antonio Collet, Director of Marketing
ABOUT Microbiome Insights, Inc. is a global leader providing end-to-end services for microbiome DNA sequencing, including state-of-the-art bioinformatic analysis. Based in Vancouver, Canada, the company’s customized suite of services enables researchers and clinicians to easily and effectively include microbiome analysis in studies across a range of human, animal, agricultural, and environmental applications. The multidisciplinary team of researchers and knowledge leaders at the company’s helm provide access to decades of expertise in traditional sciences such as ecology, microbiology, infectious diseases and genetics. Microbiome Insights’ award-winning team is committed to providing clients with fast, dependable, cost-effective results. Learn more: microbiomeinsights.com
PAGE 9
LIFE SCIENCE - READY TO ROCKET LIST FOR 2020
Navigate Surgical
ADDRESS
WEBSITE
1758 W 8th Avenue Vancouver, BC V6J 1V6 604-637-4497
www.navigatesurgical.com
PRIMARY CONTACT Marty Dymek , CEO
ABOUT Navigate Surgical Technologies develops innovative, real-time surgical navigation solutions for dental and medical applications. The company’s proprietary technology combines software and optical tracking to provide enhanced surgical precision and improved patient outcomes.
PAGE 10
LIFE SCIENCE - READY TO ROCKET LIST FOR 2020
Sitka Biopharma Inc.
ADDRESS
WEBSITE
2405 Wesbrook Mall 4th Floor Vancouver, BC V6T 1Z3 604-928-6000
www.sitkabiopharma.com TWITTER @sitkabiopharma
PRIMARY CONTACT Michael Parr, President & Chief Scientific Officer
ABOUT Sitka Biopharma is a preclinical biotechnology company focused on developing its breakthrough nanoparticle platform technology to increase absorption of drugs in difficultto-penetrate tissues. Initially targeting oncology indications, Sitka is developing its lead candidate (STK-01) to address the absorption challenge of intravesical chemotherapy for bladder cancer, and later intraperitoneal delivery for ovarian cancer. Sitka is a spin-off company of CDRD (The Centre for Drug Research and Development), and the University of British Columbia (UBC).
PAGE 11
LIFE SCIENCE - READY TO ROCKET LIST FOR 2020
Sonic Incytes Medical Corp.
ADDRESS
WEBSITE
#560-828 West 10th Ave Vancouver, BC V5Z 1M9 604-727-4145
www.sonicincytes.com
PRIMARY CONTACT George Aliphtiras, CEO
SECONDARY CONTACTs Angela Koulyras, Communications Manager
ABOUT Sonic Incytes Medical Corp. has developed a breakthrough, handheld ultrasound solution for assessing and monitoring chronic liver disease. Using technology similar to MRI elastography, our solution quantifies fat and fibrosis using 3D liver tissue sampling. Combined with machine learning to enhance image guidance, it provides a confident assessment of liver health in all body types. Sonic Incytes’ solution provides patients with a comfortable and noninvasive experience. Our procedure is easy enough to be performed by a medical assistant and produces immediate and reliable results at point of care. It can be adopted in any practice with minimal upfront investment and provides a potential new revenue stream for providers. Based in Vancouver, British Columbia, our medical device company is re-defining the standard of care in quantifying fatty liver disease—with a diagnostic solution comparable to MRI—in the palm of your hand.
PAGE 12
LIFE SCIENCE - READY TO ROCKET LIST FOR 2020
Zucara Therapeutics
ADDRESS
WEBSITE
400-2405 Wesbrook Mall Vancouver V6T 1Z3
www.zucara.ca
PRIMARY CONTACT
TWITTER @zucara_ca
Michael Midmer, CEO
ABOUT Zucara Therapeutics Inc., a spin-off company by The Centre for Drug Research and Development (CDRD) and MaRS Innovation (MI), is developing the first once-daily therapeutic to prevent hypoglycemia (low blood sugar) in patients with diabetes. Preventing hypoglycemia will dramatically change diabetes disease management, improving both patient health and quality of life.
PAGE 13
LIFE SCIENCE - READY TO ROCKET LIST FOR 2020
www.readytorocket.com
PAGE 14